Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 6Phase 3 4Phase 1/2 3Phase 2/3 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Endocrine 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 65Neoplasm Metastasis 11Advanced Breast Cancer 5Neoplasms 4Recurrence 2Multiple Endocrine Neoplasia Type 1 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Hereditary Sensory and Autonomic Neuropathies 2Unilateral Breast Neoplasms 1Neoplasms by Site 1HR-positive, HER2-negative Breast Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Disease Progression 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Breast Neoplasm Female 1Breast Diseases 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Fulvestrant × Clear all
NCT01602380 2026-02-27

FALCON

AstraZeneca

Phase 3 Completed
462 enrolled 20 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed
726 enrolled 17 charts 1 FDA
BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed
514 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡